PET drugs company Animalcare today revealed that its trading performance had continued to make progress in the first four months of the financial year.
In an update ahead of the annual general meeting, the York-based company said trading remained comfortably ahead of the previous year,and was in line with the market and the board’s expectations.
The statement added: “We continue on track to launch four new products during the year ending June 30 2013.
“The first of these Vitofyllin, a tablet prescribed for problems associated with canine ageing, was launched in September and is progressing well, with repeat orders being received. In addition, we announced on October 4 the granting of a marketing authorisation for Marbocare, an injectable presentation of the large animal antibiotic marbofloxacin. Industrial production of Marbocare is now taking place.
“The board was pleased with the underlying cash flow of the business in 2011-12 and that trend has continued in the first quarter of 2012-13. We announced in October that we are recommending a final dividend of 3.0 pence per share giving a total dividend of 4.5 pence per share for the year, up 12.5 per cent compared to 2011. Subject to shareholder approval later in the meeting, we propose to pay this dividend to shareholders on November 16 2012.”